Anand Mehta, MD
Endocrinology, Diabetes & Metabolism · San Francisco, CANPI 1992902605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 78.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 2 payments — averaging $41.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$65
- Daiichi Sankyo Inc.$17
Across 62 payments — averaging $4031.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$143K
- Eli Lilly$62K
- Vanda Pharmaceuticals Inc.$14K
- Merck$14K
- Sanofi-aventis U.S. LLC$13K
- Biohaven Pharmaceuticals, Inc.$4K
What the payments were for
- Food & beverage$83100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $65 |
| Daiichi Sankyo Inc. | 1 | $17 |
How this compares
$83 in reported general payments places this provider in the 10th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 36 | $149,762 |
| TrulicityDulaglutide | 64 | $125,886 |
| OzempicSemaglutide | 63 | $101,539 |
| Teriparatide | 37 | $85,827 |
| JardianceEmpagliflozin | 66 | $73,733 |
| MounjaroTirzepatide | 38 | $57,971 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 18 | $46,422 |
| RybelsusSemaglutide | 21 | $38,432 |
| ProliaDenosumab | 13 | $21,615 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $11,484 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $10,395 |
| Novolog FlexpenInsulin Aspart | 31 | $8,606 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $5,913 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $4,584 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 31 | $3,766 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in San Francisco
- Cheng Yang TuanSan Francisco$568K
- Lewis BlevinsSan Francisco$166K
- Wade AubrySan Francisco$79K
- Marc HellersteinSan Francisco$56K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.